Toll Free: 1-888-928-9744

Pulmonary Fibrosis - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 290 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Pulmonary Fibrosis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Pulmonary Fibrosis - Pipeline Review, H2 2014', provides an overview of the Pulmonary Fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Pulmonary Fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pulmonary Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Pulmonary Fibrosis Overview 10
Therapeutics Development 11
Pipeline Products for Pulmonary Fibrosis - Overview 11
Pipeline Products for Pulmonary Fibrosis - Comparative Analysis 12
Pulmonary Fibrosis - Therapeutics under Development by Companies 13
Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes 19
Pulmonary Fibrosis - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Pulmonary Fibrosis - Products under Development by Companies 25
Pulmonary Fibrosis - Products under Investigation by Universities/Institutes 31
Pulmonary Fibrosis - Companies Involved in Therapeutics Development 32
AdAlta Pty Ltd. 32
Aeolus Pharmaceuticals, Inc. 33
AnaptysBio, Inc. 34
Angion Biomedica Corp. 35
Aquinox Pharmaceuticals Inc. 36
Auspex Pharmaceuticals, Inc. 37
Biogen Idec Inc. 38
BiOrion Technologies B.V. 39
Boehringer Ingelheim GmbH 40
Bristol-Myers Squibb Company 41
Carolus Therapeutics, Inc. 42
Celgene Corporation 43
Chong Kun Dang Pharmaceutical Corp. 44
Compugen Ltd. 45
Corridor Pharmaceuticals Inc. 46
Digna Biotech, S.L. 47
Eli Lilly and Company 48
F. Hoffmann-La Roche Ltd. 49
FibroGen, Inc. 50
Five Prime Therapeutics, Inc. 51
Galectin Therapeutics, Inc. 52
GenKyoTex S.A. 53
Gilead Sciences, Inc. 54
GlaxoSmithKline plc 55
HanAll Biopharma Co., Ltd. 56
Histocell S.L. 57
iBio, Inc. 58
IMMD Inc. 59
ImmuneWorks, LLC 60
IntelGenx Corp. 61
InterMune, Inc. 62
Inventiva SAS 63
Kasiak Research Pvt. Ltd. 64
Kyorin Pharmaceutical Co., Ltd. 65
Lanthio Pharma B.V. 66
Lpath, Inc. 67
LTT Bio-Pharma Co., Ltd. 68
MedImmune, LLC 69
Mesoblast Limited 70
miRagen Therapeutics, Inc. 71
Moerae Matrix, Inc. 72
MSM Protein Technologies, Inc. 73
NicOx S.A. 74
Pacific Therapeutics Ltd. 75
Pharmaxis Limited 76
Pluristem Therapeutics Inc. 77
Progenra, Inc. 78
Promedior, Inc. 79
ProMetic Life Sciences Inc. 80
Pulmatrix, Inc. 81
RestorGenex Corporation 82
Rhizen Pharmaceuticals SA 83
Sanofi 84
Therametrics holding AG 85
Vectura Group plc 86
Pulmonary Fibrosis - Therapeutics Assessment 87
Assessment by Monotherapy Products 87
Assessment by Combination Products 88
Assessment by Target 89
Assessment by Mechanism of Action 93
Assessment by Route of Administration 96
Assessment by Molecule Type 98
Drug Profiles 100
(pentoxifylline + acetylcysteine) - Drug Profile 100
ABC-294640 - Drug Profile 101
AEOL-10150 - Drug Profile 103
AM-0010 - Drug Profile 106
ANG-3070 - Drug Profile 107
ANG-3298 - Drug Profile 108
Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile 109
AQX-1125 - Drug Profile 110
BB-3 - Drug Profile 112
BMS-986020 - Drug Profile 114
BOT-191 - Drug Profile 115
C-301 - Drug Profile 116
CC-539 - Drug Profile 117
CC-90001 - Drug Profile 118
CG-1011 - Drug Profile 119
CGEN-25009 - Drug Profile 120
CKD-942 - Drug Profile 121
CT-140 - Drug Profile 122
CT-2009 - Drug Profile 123
DB-02901 - Drug Profile 124
disitertide - Drug Profile 125
Drug for Idiopathic Pulmonary Fibrosis - Drug Profile 127
Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 128
FG-3019 - Drug Profile 129
FPA-008 - Drug Profile 131
GKT-137831 - Drug Profile 132
GR-MD-02 - Drug Profile 133
HC-016 - Drug Profile 135
HL-156FIB - Drug Profile 136
HR-017 - Drug Profile 137
IBIOCFB-03 - Drug Profile 138
ICG-001 - Drug Profile 139
IMD-1041 - Drug Profile 140
INT-0024 - Drug Profile 141
interferon gamma-1b - Drug Profile 142
ITMN-10534 - Drug Profile 143
ITMN-14440 - Drug Profile 144
ITMN-30162 - Drug Profile 145
IVA-337 - Drug Profile 146
IW-001 - Drug Profile 147
KBP-7018 - Drug Profile 149
lebrikizumab - Drug Profile 150
LP2 - Drug Profile 152
Lpathomab - Drug Profile 153
LT-0011 - Drug Profile 154
LY-2109761 - Drug Profile 155
MGN-4220 - Drug Profile 156
MMI-0100 - Drug Profile 157
Monoclonal Antibody for Idiopathic Pulmonary Fibrosis - Drug Profile 158
MSM-735 - Drug Profile 159
MSX-122 - Drug Profile 160
NCX-466 - Drug Profile 162
nintedanib - Drug Profile 163
Oligonucleotides for Respiratory and Oncology - Drug Profile 167
omipalisib - Drug Profile 168
P-007 - Drug Profile 169
P-17 - Drug Profile 170
P-529 - Drug Profile 172
PBF-1250 - Drug Profile 174
PBI-4050 - Drug Profile 175
phytate sodium - Drug Profile 176
pirfenidone - Drug Profile 177
PRI-724 - Drug Profile 178
PRM-151 - Drug Profile 180
PUR-1500 - Drug Profile 182
PXS-25 - Drug Profile 183
PXS-4820 - Drug Profile 184
PXS-5033-A - Drug Profile 185
PXS-64 - Drug Profile 186
Recombinant Human Follistatin - Drug Profile 187
Refacell-IPF - Drug Profile 188
RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis - Drug Profile 189
RP-6503 - Drug Profile 190
SAR-156597 - Drug Profile 191
SD-560 - Drug Profile 192
simtuzumab - Drug Profile 193
Small Molecule 1 for Chronic Respiratory Diseases - Drug Profile 195
Small Molecule 2 for Chronic Respiratory Diseases - Drug Profile 196
Small Molecule to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile 197
Small Molecule to Inhibit NOX 1 and 4 - Drug Profile 198
Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis - Drug Profile 199
Small Molecules to Inhibit LOXL2 for Oncology and Fibrosis - Drug Profile 200
Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis - Drug Profile 201
SPL-334 - Drug Profile 202
Stem Cell Therapy for Asthma and Pulmonary Fibrosis - Drug Profile 203
Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile 204
Stem Cell Therapy for Pulmonary Fibrosis - Drug Profile 205
STX-100 - Drug Profile 206
Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 207
Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury - Drug Profile 209
TD-139 - Drug Profile 210
tipelukast - Drug Profile 212
tralokinumab - Drug Profile 214
vismodegib - Drug Profile 216
Pulmonary Fibrosis - Recent Pipeline Updates 219
Pulmonary Fibrosis - Dormant Projects 267
Pulmonary Fibrosis - Discontinued Products 271
Pulmonary Fibrosis - Product Development Milestones 272
Featured News & Press Releases 272
Appendix 282
Methodology 282
Coverage 282
Secondary Research 282
Primary Research 282
Expert Panel Validation 282
Contact Us 283
Disclaimer 283
List of Tables
Number of Products under Development for Pulmonary Fibrosis, H2 2014 18
Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H2 2014 19
Number of Products under Development by Companies, H2 2014 21
Number of Products under Development by Companies, H2 2014 (Contd..1) 22
Number of Products under Development by Companies, H2 2014 (Contd..2) 23
Number of Products under Development by Companies, H2 2014 (Contd..3) 24
Number of Products under Development by Companies, H2 2014 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H2 2014 27
Comparative Analysis by Late Stage Development, H2 2014 28
Comparative Analysis by Clinical Stage Development, H2 2014 29
Comparative Analysis by Early Stage Development, H2 2014 30
Comparative Analysis by Unknown Stage Development, H2 2014 31
Products under Development by Companies, H2 2014 32
Products under Development by Companies, H2 2014 (Contd..1) 33
Products under Development by Companies, H2 2014 (Contd..2) 34
Products under Development by Companies, H2 2014 (Contd..3) 35
Products under Development by Companies, H2 2014 (Contd..4) 36
Products under Development by Companies, H2 2014 (Contd..5) 37
Products under Investigation by Universities/Institutes, H2 2014 38
Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H2 2014 39
Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2014 40
Pulmonary Fibrosis - Pipeline by AnaptysBio, Inc., H2 2014 41
Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp., H2 2014 42
Pulmonary Fibrosis - Pipeline by Aquinox Pharmaceuticals Inc., H2 2014 43
Pulmonary Fibrosis - Pipeline by Auspex Pharmaceuticals, Inc., H2 2014 44
Pulmonary Fibrosis - Pipeline by Biogen Idec Inc., H2 2014 45
Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2014 46
Pulmonary Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H2 2014 47
Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2014 48
Pulmonary Fibrosis - Pipeline by Carolus Therapeutics, Inc., H2 2014 49
Pulmonary Fibrosis - Pipeline by Celgene Corporation, H2 2014 50
Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 51
Pulmonary Fibrosis - Pipeline by Compugen Ltd., H2 2014 52
Pulmonary Fibrosis - Pipeline by Corridor Pharmaceuticals Inc., H2 2014 53
Pulmonary Fibrosis - Pipeline by Digna Biotech, S.L., H2 2014 54
Pulmonary Fibrosis - Pipeline by Eli Lilly and Company, H2 2014 55
Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 56
Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H2 2014 57
Pulmonary Fibrosis - Pipeline by Five Prime Therapeutics, Inc., H2 2014 58
Pulmonary Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2014 59
Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H2 2014 60
Pulmonary Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2014 61
Pulmonary Fibrosis - Pipeline by GlaxoSmithKline plc, H2 2014 62
Pulmonary Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 63
Pulmonary Fibrosis - Pipeline by Histocell S.L., H2 2014 64
Pulmonary Fibrosis - Pipeline by iBio, Inc., H2 2014 65
Pulmonary Fibrosis - Pipeline by IMMD Inc., H2 2014 66
Pulmonary Fibrosis - Pipeline by ImmuneWorks, LLC, H2 2014 67
Pulmonary Fibrosis - Pipeline by IntelGenx Corp., H2 2014 68
Pulmonary Fibrosis - Pipeline by InterMune, Inc., H2 2014 69
Pulmonary Fibrosis - Pipeline by Inventiva SAS, H2 2014 70
Pulmonary Fibrosis - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 71
Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2014 72
Pulmonary Fibrosis - Pipeline by Lanthio Pharma B.V., H2 2014 73
Pulmonary Fibrosis - Pipeline by Lpath, Inc., H2 2014 74
Pulmonary Fibrosis - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2014 75
Pulmonary Fibrosis - Pipeline by MedImmune, LLC, H2 2014 76
Pulmonary Fibrosis - Pipeline by Mesoblast Limited, H2 2014 77
Pulmonary Fibrosis - Pipeline by miRagen Therapeutics, Inc., H2 2014 78
Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H2 2014 79
Pulmonary Fibrosis - Pipeline by MSM Protein Technologies, Inc., H2 2014 80
Pulmonary Fibrosis - Pipeline by NicOx S.A., H2 2014 81
Pulmonary Fibrosis - Pipeline by Pacific Therapeutics Ltd., H2 2014 82
Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H2 2014 83
Pulmonary Fibrosis - Pipeline by Pluristem Therapeutics Inc., H2 2014 84
Pulmonary Fibrosis - Pipeline by Progenra, Inc., H2 2014 85
Pulmonary Fibrosis - Pipeline by Promedior, Inc., H2 2014 86
Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2014 87
Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H2 2014 88
Pulmonary Fibrosis - Pipeline by RestorGenex Corporation, H2 2014 89
Pulmonary Fibrosis - Pipeline by Rhizen Pharmaceuticals SA, H2 2014 90
Pulmonary Fibrosis - Pipeline by Sanofi, H2 2014 91
Pulmonary Fibrosis - Pipeline by Therametrics holding AG, H2 2014 92
Pulmonary Fibrosis - Pipeline by Vectura Group plc, H2 2014 93
Assessment by Monotherapy Products, H2 2014 94
Assessment by Combination Products, H2 2014 95
Number of Products by Stage and Target, H2 2014 97
Number of Products by Stage and Mechanism of Action, H2 2014 101
Number of Products by Stage and Route of Administration, H2 2014 104
Number of Products by Stage and Molecule Type, H2 2014 106
Pulmonary Fibrosis Therapeutics - Recent Pipeline Updates, H2 2014 226
Pulmonary Fibrosis - Dormant Projects, H2 2014 274
Pulmonary Fibrosis - Dormant Projects (Contd..1), H2 2014 275
Pulmonary Fibrosis - Dormant Projects (Contd..2), H2 2014 276
Pulmonary Fibrosis - Dormant Projects (Contd..3), H2 2014 277
Pulmonary Fibrosis - Discontinued Products, H2 2014 278 



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify